SubQSA

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
64 patients (estimated)
Sponsors
Sanofi
Tags
Monoclonal Antibody, CD38
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
2068
NCT Identifier
NCT06356571

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.